<DOC>
	<DOCNO>NCT00404924</DOCNO>
	<brief_summary>This study carry assess add ZD6474 best supportive care ( BSC ) effective best supportive care alone , treatment patient non-small cell lung cancer , whose disease recur previous chemotherapy Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ( EGFR TKI ) . ZD6474 new anti-cancer drug development work different way standard chemotherapy drug . It target growth new blood vessel tumour thereby might slow rate tumour may grow . Early study indicate ZD6474 positive effect time tumour may take progress stage . Approximately 930 patient take part study . It conduct hospital clinic North South America , Europe Asia .</brief_summary>
	<brief_title>ZD6474 ( ZACTIMAâ„¢ ) Phase III Study EGFR Failures</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients Nonsmall cell lung cancer standard cancer treatment surgery , chemotherapy , radiation anticancer drug longer appropriate treatment . Patients standard cancer treatment surgery , chemotherapy systemic anticancer therapy within 4 week start study therapy . Three prior chemotherapy regimen . Significant cardiovascular event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-Small-Cell Lung Carcinoma</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Large Cell Carcinoma</keyword>
</DOC>